PSMA-Targeted Radioligand Therapy: Before or After Cabazitaxel
Both cabazitaxel and Lu-177-PSMA-617 are real options after progression on docetaxel and an ARPI — the actual argument is over sequencing, and whether uniformly high PSMA avidity combined with early myelosuppression should move the radioligand ahead of another taxane.
J.K., a 68-year-old man, has spent most weekends for the last thirty years restoring a 1967 pickup truck that belonged to his late father, work he says keeps his hands and his mind busy in equal measure. His metastatic castration-resistant prostate cancer has already been treated with docetaxel and enzalutamide, both eventually exhausted by progression, leaving him at the exact point in the disease course where cabazitaxel and Lu-177-PSMA-617 both become genuine options — he has met the specific prior-therapy requirement, post-taxane and post-ARPI, that defines eligibility for either. A PSMA PET/CT obtained for staging showed uniformly high uptake across every site of disease, SUVmax well above the threshold VISION used to define eligibility, with no site of disease PSMA-negative or discordant on conventional imaging.
VISION established Lu-177-PSMA-617's overall survival benefit specifically in this post-taxane, post-ARPI population — a median survival advantage of several months over standard of care alone, alongside a substantially longer radiographic progression-free survival — and his uniformly high PSMA avidity is close to the most favorable imaging profile that trial's own eligibility criteria could describe. Cabazitaxel, by contrast, has a longer track record in this exact setting, with its own demonstrated survival benefit over mitoxantrone in TROPIC, the trial that first established its role after docetaxel, and a more familiar toxicity profile for the treating team — but it carries meaningful myelosuppression risk that compounds directly with his prior docetaxel exposure, and his most recent counts already show early, measurable suppression: hemoglobin 11.4, platelets down from his pre-chemotherapy baseline. Both regimens require recurring intravenous administration, a logistical detail he has raised himself, since travel to and from the infusion center cuts directly into the weekend hours he would rather spend with his father's truck.
Choosing the next line after two prior therapies
His PSMA PET is about as favorable as this imaging gets — uniformly high uptake, no discordant or PSMA-negative sites anywhere. VISION established the overall survival benefit for Lu-177-PSMA-617 in exactly this post-taxane, post-ARPI setting. On top of that, his counts already show real myelosuppression from docetaxel — hemoglobin 11.4, platelets down from baseline. The radioligand's incremental hematologic toxicity is generally milder than another cytotoxic taxane layered on that existing suppression. Both the imaging and the blood work point the same direction.
I want to push on the count argument specifically, because I think it's being used backwards. Lu-177-PSMA-617 is not marrow-sparing — VISION reported more grade 3 or higher anemia, thrombocytopenia and lymphopenia on the radioligand arm than on standard care, and the marrow taking that dose is the same marrow his docetaxel already suppressed. A hemoglobin of 11.4 and falling platelets are a reason for caution about both options, not an argument that selects between them. And VISION's comparator was physician's choice of standard care with cabazitaxel largely excluded by design, so it never established superiority over the drug we're actually weighing it against.
I end up at the radioligand too, but on the imaging alone — uniformly high avidity is a genuinely favorable selection marker and TROPIC's population was not selected that way. I want the record to show it's the PSMA PET carrying this decision, not the blood counts, because if his counts are the reason we chose it we've reasoned our way into the wrong drug.
Agreed: Lu-177-PSMA-617 started, with baseline and interval CBC monitoring given his prior docetaxel exposure, and repeat PSMA PET after two cycles to confirm ongoing avidity before continuing.
Not agreed, and named explicitly as an open question rather than resolved by today's decision:
Would treat this same imaging-plus-counts reasoning as a general basis for prioritizing radioligand therapy earlier in similarly-profiled patients going forward.
Would want a direct comparative trial before treating today's reasoning as anything more than a well-justified individual decision for this specific patient.